Indivior PLC (INDV)

209.80
+2.20(+1.06%)
  • Volume:
    1,986,073
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    206.40 - 213.60

INDV Overview

Prev. Close
207.6
Day's Range
206.4-213.6
Revenue
526.57M
Open
207
52 wk Range
67-213.69
EPS
0.13
Volume
1,986,073
Market Cap
1.52B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,381,776
P/E Ratio
16.17
Beta
-0.38
1-Year Change
72.53%
Shares Outstanding
725,541,606
Next Earnings Date
04 Nov 2021
What is your sentiment on Indivior PLC?
or
Market is currently closed. Voting is open during market hours.

Indivior PLC News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Indivior PLC Company Profile

Indivior PLC Company Profile

Employees
819

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia. Its products are Suboxone Film (buprenorphine and naloxone), Suboxone Tablet (buprenorphine and naloxone), and Subutex Tablet (buprenorphine). Its other products include RBP-6000 in ATRIGEL, RBP-7000 risperidone monthly depot, Arbaclofen placarbil for alcohol use disorder (AUD), Intranasal naloxone for treatment of opioid overdose and RBP-8000 cocaine esterase for cocaine intoxication. Its RBP-6000 buprenorphine monthly depot is developed for the treatment of opioid use disorder. Its RBP-7000 risperidone monthly depot is developed for treatment of schizophrenia.

Read More
  • What a poor business. Extrodinary debt. No cash.
    1
    • totally agree. this is the crazy stock.
      0
  • potential 3 bln fines in US. company is broke.
    0
    • company tried settlement but rejected.the previous parent company has already set aside 400 million.
      0
  • any ideas
    1
    • where this will stop
      1
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.